Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.

ABSTRACT:

Background

Assays used for discovery of biomarkers should be robust and high-throughput, capable of analyzing a sufficiently large number of samples over a sufficiently long period of time with good precision.

Methods

We evaluated the analytical performance of the Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex multiplex immunoassay, in serum for composite profiling of angiogenic factors. Because prostate cancer progression and metastasis are pathological events closely linked to angiogenesis, serum angiogenic factors are ideal candidates as prognostic biomarkers.

Results

Our 5-day evaluation indicated that all 16 assays in the panel had good reproducibility (total precisions over 5 independent plates in 5 days of <20%), adequate sensitivity (LOQs of majority

SUBMITTER: Li D 

PROVIDER: S-EPMC4086634 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature